Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3857210 ISA
LY3857210 · 3 trials · 3 indications
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. The data presented are the posterior mean with a 95% credible interval.
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0=no pain, and 10=pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
| Arm | Type | Description |
|---|---|---|
| LY3857210 | EXPERIMENTAL | Participants received 45 milligrams (mg) of LY3857210 orally once daily for up to 8 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants received placebo orally once daily for up to 8 weeks. |
| 45 mg LY3857210 | EXPERIMENTAL | Participants received 45 milligram (mg) LY3857210 orally once daily for up to 8 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3857210 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have a visual analog scale (VAS) pain value ≥40 and \<95 during screening. * Have a history of daily pain for at least 12 weeks based on participant report or medical history. * Have a body mass index \<40 kilograms per meter squared (kg/m²) (inclusive). * Are willing to maint...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 2 | PHASE3 | Camlipixant |
| Trevi Therapeutics, Inc. | TRVI | 1 | PHASE2 | Haduvio (nalbuphine ER) |
LY3857210 is an investigational small molecule being developed by Eli Lilly and Company for chronic pain. It has been studied in Phase 2 clinical trials for chronic low-back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain. It is not yet approved for any indication and remains in clinical development.
LY3857210 is being studied for the treatment of chronic pain conditions, specifically chronic low-back pain, diabetic peripheral neuropathic pain, and osteoarthritis pain. All three Phase 2 trials in these indications have been completed. The drug is investigational and has not been approved for any use.
LY3857210 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 2 chronic pain master protocol studies evaluating the compound across multiple pain indications.
LY3857210 is in Phase 2 development. Three Phase 2 trials under a chronic pain master protocol have been completed, and the drug is investigational, meaning it has not received FDA approval for any indication.
LY3857210 has been evaluated in three completed Phase 2 trials: NCT05630196 in chronic low-back pain, NCT05620576 in diabetic peripheral neuropathic pain, and NCT05620563 in osteoarthritis pain. All were randomized, double-blind, placebo-controlled studies conducted in the United States and Puerto Rico.
Yes, LY3857210 ISA is an alternative name for LY3857210, the investigational small molecule developed by Eli Lilly and Company for chronic pain. Searches for either name refer to the same compound.